[Federal Register Volume 83, Number 40 (Wednesday, February 28, 2018)]
[Notices]
[Pages 8672-8674]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-04025]
=======================================================================
-----------------------------------------------------------------------
FEDERAL TRADE COMMISSION
[File No. 142 3103]
Telomerase Activation Sciences, Inc. and Noel Thomas Patton;
Analysis To Aid Public Comment
AGENCY: Federal Trade Commission.
ACTION: Proposed consent agreement.
-----------------------------------------------------------------------
SUMMARY: The consent agreement in this matter settles alleged
violations of federal law prohibiting unfair or deceptive acts or
practices. The attached Analysis to Aid Public Comment describes both
the allegations in the complaint and the terms of the consent order--
embodied in the consent agreement--that would settle these allegations.
DATES: Comments must be received on or before March 23, 2018.
ADDRESSES: Interested parties may file a comment online or on paper, by
following the instructions in the Request for Comment part of the
SUPPLEMENTARY INFORMATION section below. Write: ``In the Matter of
Telomerase Activation Sciences, Inc., et al.'' on your comment, and
file your comment online at https://ftcpublic.commentworks.com/ftc/telomeraseconsent by following the instructions on the web-based form.
If you prefer to file your comment on paper, write ``In the Matter of
Telomerase Activation Sciences, Inc., et al.'' on your comment and on
the envelope, and mail your comment to the following address: Federal
Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW,
Suite CC-5610 (Annex D), Washington, DC 20580, or deliver your comment
to the following address: Federal Trade Commission, Office of the
Secretary, Constitution Center, 400 7th Street SW, 5th Floor, Suite
5610 (Annex D), Washington, DC 20024.
FOR FURTHER INFORMATION CONTACT: Andrew Wone (202-326-2934), Bureau of
Consumer Protection, 600 Pennsylvania Avenue NW, Washington, DC 20580.
SUPPLEMENTARY INFORMATION: Pursuant to Section 6(f) of the Federal
Trade Commission Act, 15 U.S.C. 46(f), and FTC Rule 2.34, 16 CFR 2.34,
notice is hereby given that the above-captioned consent agreement
containing a consent order to cease and desist, having been filed with
and accepted, subject to final approval, by the Commission, has been
placed on the public record for a period of thirty (30) days. The
following Analysis to Aid Public Comment describes the terms of the
consent agreement, and the allegations in the complaint. An electronic
copy of the full text of the consent agreement package can be obtained
from the FTC Home Page (for February 21, 2018), on the World Wide Web,
at https://www.ftc.gov/news-events/commission-actions.
You can file a comment online or on paper. For the Commission to
consider your comment, we must receive it on or before March 23, 2018.
Write ``In the Matter of Telomerase Activation Sciences, Inc., et al.''
on your comment. Your comment--including your name and your state--will
be placed on the public record of this proceeding, including, to the
extent practicable, on the public Commission website, at https://www.ftc.gov/policy/public-comments.
Postal mail addressed to the Commission is subject to delay due to
heightened security screening. As a result, we encourage you to submit
your comments online. To make sure that the Commission considers your
online comment, you must file it at https://ftcpublic.commentworks.com/ftc/telomeraseconsent by following the instructions on the web-based
form. If this Notice appears at http://www.regulations.gov/#!home, you
also may file a comment through that website.
If you prefer to file your comment on paper, write ``In the Matter
of Telomerase Activation Sciences, Inc., et al.'' on your comment and
on the envelope, and mail your comment to the following address:
Federal Trade Commission, Office of the Secretary, 600 Pennsylvania
Avenue NW, Suite CC-5610 (Annex D), Washington, DC 20580, or deliver
your comment to the following address: Federal Trade Commission, Office
of the Secretary, Constitution Center, 400 7th Street SW, 5th Floor,
Suite 5610 (Annex D), Washington, DC 20024. If possible, submit your
paper comment to the Commission by courier or overnight service.
Because your comment will be placed on the publicly accessible FTC
website at https://www.ftc.gov, you are solely responsible for making
sure that your comment does not include any sensitive or confidential
information. In particular, your comment should not include any
sensitive personal information, such as your or anyone else's Social
Security number; date of birth; driver's license number or other state
identification number, or foreign country equivalent; passport number;
financial account number; or credit or debit card number. You are also
solely responsible for making sure that your comment does not include
any sensitive health information, such as medical records or other
individually identifiable health information. In addition, your comment
should not include any ``trade secret or any commercial or financial
information which . . . is privileged or confidential''--as provided by
Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2),
16 CFR 4.10(a)(2)--including in particular competitively sensitive
information such as costs,
[[Page 8673]]
sales statistics, inventories, formulas, patterns, devices,
manufacturing processes, or customer names.
Comments containing material for which confidential treatment is
requested must be filed in paper form, must be clearly labeled
``Confidential,'' and must comply with FTC Rule 4.9(c). In particular,
the written request for confidential treatment that accompanies the
comment must include the factual and legal basis for the request, and
must identify the specific portions of the comment to be withheld from
the public record. See FTC Rule 4.9(c). Your comment will be kept
confidential only if the General Counsel grants your request in
accordance with the law and the public interest. Once your comment has
been posted on the public FTC website--as legally required by FTC Rule
4.9(b)--we cannot redact or remove your comment from the FTC website,
unless you submit a confidentiality request that meets the requirements
for such treatment under FTC Rule 4.9(c), and the General Counsel
grants that request.
Visit the FTC website at http://www.ftc.gov to read this Notice and
the news release describing it. The FTC Act and other laws that the
Commission administers permit the collection of public comments to
consider and use in this proceeding, as appropriate. The Commission
will consider all timely and responsive public comments that it
receives on or before March 23, 2018. For information on the
Commission's privacy policy, including routine uses permitted by the
Privacy Act, see https://www.ftc.gov/site-information/privacy-policy.
Analysis of Proposed Consent Order To Aid Public Comment
The Federal Trade Commission (``FTC'' or ``Commission'') has
accepted, subject to final approval, an agreement containing a consent
order as to Telomerase Activation Sciences, Inc. and Noel Thomas Patton
(collectively ``respondents'').
The proposed consent order (``order'') has been placed on the
public record for 30 days for receipt of comments by interested
persons. Comments received during this period will become part of the
public record. After 30 days, the Commission will again review the
agreement and the comments received, and will decide whether it should
withdraw from the agreement or make final the agreement's order.
This matter involves respondents' advertising for TA-65MD, a
product that comes in capsule and powder forms, and TA-65 for Skin
(``TA-65 Skin''), a topical cream product. The complaint alleges that
respondents violated Sections 5(a) and 12 of the FTC Act by making
false or unsubstantiated health or performance claims that: TA-65MD and
TA-65 Skin reverse aging; TA-65MD prevents and repairs DNA damage; TA-
65MD restores aging immune systems; TA-65MD increases bone density; TA-
65MD reverses the effects of aging, including improving skin
elasticity, increasing energy and endurance, and improving vision; TA-
65MD prevents or reduces the risk of cancer; TA-65 Skin reverses the
effects of aging, including improving skin elasticity; and TA-65 Skin
decreases recovery time of the skin after medical procedures. The
complaint also alleges that respondents claimed that some of the above
performance claims were clinically or scientifically proven.
The complaint further alleges that respondents misrepresented that
a 2012 paid-for segment on The Suzanne Show featuring TA-65MD was
independent, educational programming and not paid commercial
advertising. Additionally, the complaint alleges that respondents
deceptively represented that consumers appearing in advertisements were
independent users of TA-65MD, expressing their impartial views of
satisfaction. According to the complaint, respondents failed to
disclose that these consumer endorsers received compensation, including
free TA-65MD. Finally, the complaint alleges that by providing
promotional materials that had false or unsubstantiated health or
performance claims to marketers of other products containing TA-65MD,
respondents provided these other marketers the means and
instrumentalities to engage in deceptive acts and practices.
The order includes injunctive relief that prohibits these alleged
violations and fences in similar and related violations. The order
applies to marketing claims for any covered product, defined as TA-65MD
and TA-65 Skin or any other drug, food, dietary supplement, or
cosmetic. As additional fencing-in relief, the order requires
respondents to provide a notice to all of its licensees authorized to
advertise, market, or sell any covered product, monitor certain high-
selling licensees, and follow appropriate recordkeeping, compliance
reporting, and document preservation requirements.
Provision I prohibits any representation that a covered product
reverses human aging; prevents or repairs DNA damage; restores aging
immune systems; increases bone density; reverses the effects of aging,
including improving skin elasticity, increasing energy and endurance,
and improving vision; decreases recovery time of the skin after medical
procedures; prevents or reduces the risk of cancer; or cures,
mitigates, or treats any disease unless the representation is non-
misleading and respondents possess and rely upon competent and reliable
scientific evidence that substantiates that the representation is true.
The definition of competent and reliable scientific evidence in
Provision I specifies human clinical testing and requires that the
testing be sufficient in quality and quantity, based on standards
generally accepted by experts in the relevant disease, condition, or
function to which the representation relates, when considered in light
of the entire body of relevant and reliable scientific evidence, to
substantiate that the representation is true. Such testing must (1) be
randomized, double-blind, and placebo-controlled; and (2) be conducted
by researchers qualified by training and experience to conduct such
testing. In addition, respondents must maintain all underlying or
supporting data and documents generally accepted by experts in the
field as relevant to an assessment of such testing.
Provision II prohibits representations regarding the health
benefits, performance, efficacy, safety, or side effects of any covered
product unless the representation is non-misleading and respondents
possess and rely upon competent and reliable scientific evidence to
substantiate that the representation is true. Provision II defines
competent and reliable scientific evidence as tests, analyses,
research, or studies: (1) That have been conducted and evaluated in an
objective manner by experts in the relevant disease, condition, or
function to which the representation relates; (2) that are generally
accepted by such experts to yield accurate and reliable results; and
(3) that are randomized, double-blind, and placebo-controlled human
clinical testing of the covered product, when such experts would
generally require such human clinical testing to substantiate that the
representation is true. When such tests or studies are human clinical
tests or studies, respondents must maintain all underlying or
supporting data and documents generally accepted by experts in the
field as relevant to an assessment of such testing.
Provision III prohibits misrepresentations that any covered product
is clinically or scientifically proven to reverse human aging, prevent
or repair DNA damage, restore aging immune systems, or increase bone
density. Provision III also prohibits any misrepresentation that the
performance
[[Page 8674]]
or benefits of any product are scientifically or clinically proven or
about the existence, contents, validity, results, conclusions, or
interpretations of any test, study, or research.
Provision IV is a provision for FDA-approved claims.
Provision V prohibits misrepresentations in connection with the
marketing, advertising, or promoting of any product, service, or
program that paid commercial advertising is independent programming.
Provision VI prohibits any representation about any user, consumer,
or endorser of a covered product without disclosing, clearly and
conspicuously, and in close proximity to that representation, any
unexpected material connection between such endorser and (1) any
respondent; or (2) any other individual or entity affiliated with the
product. ``Unexpected material connection'' means any relationship that
might materially affect the weight or credibility of the testimonial or
endorsement and that would not reasonably be expected by consumers.
Provision VII prohibits misrepresentations regarding the status of
any endorser or person providing a review of a product, including a
misrepresentation that the endorser or reviewer is an independent or
ordinary user of the product.
Provision VIII prohibits respondents from providing the means and
instrumentalities to make any false or misleading statement of material
fact, including the representations prohibited by Provisions I to III.
``Means and instrumentalities'' mean any information, document, or
article referring or relating to any covered product, including any
advertising, labeling, promotional, or purported substantiation
materials, for use by a licensee to market or sell any covered product.
Provision IX, triggered when the human clinical testing requirement
in Provisions I or II applies, requires that respondents secure and
preserve all underlying or supporting data and documents generally
accepted by experts in the field as relevant to an assessment of the
test, such as protocols, instructions, participant-specific data,
statistical analyses, and contracts with the test's researchers. There
is an exception for a reliably reported test (defined as a test that is
published in a peer-reviewed journal) that was not conducted,
controlled, or sponsored by, with, or on behalf of any respondent or by
any supplier or manufacturer of the product. Also, the published report
must provide sufficient information about the test for experts in the
relevant field to assess the reliability of the results.
Provision X mandates that respondents acknowledge receipt of the
order, distribute the order to principals, officers, and certain
employees and agents, and obtain signed acknowledgments from them.
Provision XI requires that respondents submit compliance reports to
the FTC 60 days after the order's issuance and submit notifications
when certain events occur for 10 years.
Provision XII requires that respondents create and retain certain
records for 10 years.
Provision XIII provides for the FTC's continued compliance
monitoring of respondents' activities during the order's effective
dates.
Provision XIV requires that respondents notify their licensees,
monitor their highest-selling licensees' advertising to ensure
compliance with Provisions I through III, and suspend any licensee who
makes any prohibited claims. Respondents must terminate any licensee
who continues to make prohibited claims. There are two limited
exceptions to the monitoring requirement: (1) Representations during
private consultations between a licensee and one of the licensee's
patients about the potential safety, health benefits, performance,
efficacy, or side effects of a covered product; and (2) representations
about the potential safety, health benefits, performance, efficacy, or
side effects of a covered product by a licensee who has purchased a
covered product solely for incorporation into the licensee's own
product and markets that product without any involvement by
respondents.
Provision XV requires that respondents send a notice to all
customers who purchased directly from them TA-65MD or TA-65 Skin within
one year prior to the issuance of the order or through a currently
active enrollment in a continuity or autoship program.
Provision XVI provides that, with exceptions, the order will
terminate in 20 years.
The purpose of this analysis is to facilitate public comment on the
order, and it is not intended to constitute an official interpretation
of the complaint or order, or to modify the order's terms in any way.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2018-04025 Filed 2-27-18; 8:45 am]
BILLING CODE 6750-01-P